Fransson M - Search Results

1

T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.

Burman J, Fransson M, Tötterman TH, Fagius J, Mangsbo SM, Loskog AS. Burman J, et al. Among authors: fransson m. Immunology. 2013 Oct;140(2):211-9. doi: 10.1111/imm.12129. Immunology. 2013. PMID: 23721329 Free PMC article.

2

T regulatory cells lacking CD25 are increased in MS during relapse.

Fransson M, Burman J, Lindqvist C, Atterby C, Fagius J, Loskog A. Fransson M, et al. Autoimmunity. 2010 Dec;43(8):590-7. doi: 10.3109/08916930903541190. Epub 2010 Apr 7. Autoimmunity. 2010. PMID: 20370571

3

Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis.

Fransson M, Piras E, Wang H, Burman J, Duprez I, Harris RA, LeBlanc K, Magnusson PU, Brittebo E, Loskog AS. Fransson M, et al. Immunology. 2014 Jul;142(3):431-41. doi: 10.1111/imm.12275. Immunology. 2014. PMID: 24588452 Free PMC article.

4

The cerebrospinal fluid cytokine signature of multiple sclerosis: a homogenous response that does not conform to the Th1/Th2/Th17 convention.

Burman J, Svensson E, Fransson M, Loskog AS, Zetterberg H, Raininko R, Svenningsson A, Fagius J, Mangsbo SM. Burman J, et al. Among authors: fransson m. J Neuroimmunol. 2014 Dec 15;277(1-2):153-9. doi: 10.1016/j.jneuroim.2014.10.005. Epub 2014 Oct 18. J Neuroimmunol. 2014. PMID: 25457841

5

The T-cell pool is anergized in patients with multiple sclerosis in remission.

Fransson ME, Liljenfeldt LS, Fagius J, Tötterman TH, Loskog AS. Fransson ME, et al. Immunology. 2009 Jan;126(1):92-101. doi: 10.1111/j.1365-2567.2008.02881.x. Epub 2008 Jun 24. Immunology. 2009. PMID: 18624727 Free PMC article.

6

Assessing tissue damage in multiple sclerosis: a biomarker approach.

Burman J, Zetterberg H, Fransson M, Loskog AS, Raininko R, Fagius J. Burman J, et al. Among authors: fransson m. Acta Neurol Scand. 2014 Aug;130(2):81-9. doi: 10.1111/ane.12239. Epub 2014 Feb 24. Acta Neurol Scand. 2014. PMID: 24571714

7

AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.

Malmström PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A, Gårdmark T, Tötterman TH. Malmström PU, et al. Among authors: fransson m. Clin Cancer Res. 2010 Jun 15;16(12):3279-87. doi: 10.1158/1078-0432.CCR-10-0385. Epub 2010 May 4. Clin Cancer Res. 2010. PMID: 20448220 Clinical Trial.

8

CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery.

Fransson M, Piras E, Burman J, Nilsson B, Essand M, Lu B, Harris RA, Magnusson PU, Brittebo E, Loskog AS. Fransson M, et al. J Neuroinflammation. 2012 May 30;9:112. doi: 10.1186/1742-2094-9-112. J Neuroinflammation. 2012. PMID: 22647574 Free PMC article.

9

AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model.

Loskog AS, Fransson ME, Totterman TT. Loskog AS, et al. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8816-21. doi: 10.1158/1078-0432.CCR-05-1817. Clin Cancer Res. 2005. PMID: 16361570

10

Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition.

Lindqvist C, Sandin LC, Fransson M, Loskog A. Lindqvist C, et al. Among authors: fransson m. J Immunother. 2009 Oct;32(8):785-92. doi: 10.1097/CJI.0b013e3181acea69. J Immunother. 2009. PMID: 19752755

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

76 results

Search Page